NIKKEI 225
40,913.65 +332.89 (+0.82%) HANG SENG
18,019.31 +40.74 (+0.23%) CRUDE OIL
83.27 -0.61 (-0.73%) GOLD FUTURES
2,369.40 0.00 (0.00%) DOW
39,308.00 -23.90 (-0.06%) Bitcoin GBP
46,163.15 -1,615.59 (-3.38%)
ANVS Jul 2024 5.000 call
| Previous close | 4.2000 |
| Open | 3.9000 |
| Bid | 2.0000 |
| Ask | 3.4000 |
| Strike | 5.00 |
| Expiry date | 2024-07-19 |
| Day's range | 2.5000 - 3.9000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
- Yahoo Finance Video
Annovis Bio shares dip on phase III Parkinson's trial data
Annovis Bio (ANVS) released new data from its phase III Parkinson's study. The data shows that cognition improvements were made in patients after treatment. Yahoo Finance Reporter Anjalee Khemlani joins Market Domination to explain why the biotechnology company's shares are declining despite the positive trial results. For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Nicholas Jacobino
ZacksAnnovis (ANVS) Up as Its Lead Candidate Meets Goals in PD Study
Annovis (ANVS) surges 76% on Jul 2 after meeting the primary and secondary goals with statistical significance in the late-stage PD study of its lead candidate, buntanetap.
GlobeNewswireAnnovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
Changes in MMSE after treatment with 10mg or 20mg buntanetap compared to baseline and placebo Figure 1. Changes in MDS-UPDRS after treatment with 10mg or 20mg buntanetap in patients with a PD diagnosis over 3 years compared to baseline and placebo Figure 2. Changes in MDS-UPDRS after treatment with 10mg or 20mg buntanetap in patients with PIGD Figure 3. Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinson’s pati
